Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies

MLA

Zhenan Deng, et al. “Eligibility of C-BIOPRED Severe Asthma Cohort for Type-2 Biologic Therapies.” Chinese Medical Journal, vol. 136, no. 2, Jan. 2023, pp. 230–32. EBSCOhost, https://doi.org/10.1097/CM9.0000000000002556.

APA

Zhenan Deng, Meiling Jin, Changxing Ou, Wei Jiang, Jianping Zhao, Xiaoxia Liu, Shenghua Sun, Huaping Tang, Bei He, Shaoxi Cai, Ping Chen, Penghui Wu, Yujing Liu, Jian Kang, Yunhui Zhang, Mao Huang, Jinfu Xu, Kewu Huang, Qiang Li, … Lishao Guo. (2023). Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies. Chinese Medical Journal, 136(2), 230–232. https://doi.org/10.1097/CM9.0000000000002556

Chicago

Zhenan Deng, Meiling Jin, Changxing Ou, Wei Jiang, Jianping Zhao, Xiaoxia Liu, Shenghua Sun, et al. 2023. “Eligibility of C-BIOPRED Severe Asthma Cohort for Type-2 Biologic Therapies.” Chinese Medical Journal 136 (2): 230–32. doi:10.1097/CM9.0000000000002556.